Which emotion regulation strategies are mediating the outcome of acceptance and commitment therapy compared to cognitive-behaviour therapy in the treatment of anxiety symptoms?

Psychother ResSep 16, 2025 (epub)
Clinical ResearchPsychiatry

Philip Spinhoven, Vivian Kraaij, Nadia Garnefski et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined whether changes in emotion regulation strategies explained differences between acceptance and commitment therapy (ACT) and cognitive-behaviour therapy (CBT) for anxiety symptoms in 314 older adults. Participants completed self-report measures of anxiety and proposed mediators five times during treatment. ACT differentially affected acceptance, suppression, and distraction, while changes in most mediators were associated with anxiety outcomes at the same time point. However, no emotion regulation variable mediated ACT’s effect; cognitive reappraisal alone predicted subsequent anxiety levels, and anxiety also predicted later reappraisal, irrespective of treatment.

Key findings

  • ACT differentially affected acceptance, suppression, and distraction compared with CBT.
  • Changes in all proposed mediators except acceptance had significant cross-sectional associations with anxiety outcomes.
  • Cognitive reappraisal predicted subsequent anxiety levels, and anxiety predicted subsequent reappraisal, irrespective of treatment.
  • None of the emotion regulation variables mediated the effect of ACT.

Why it matters

The findings distinguish concurrent associations from evidence that a process precedes and explains treatment outcomes. Although several emotion regulation strategies changed differently between therapies or tracked with anxiety, the longitudinal analyses did not support them as mediators of ACT’s effect. This cautions against assuming that a strategy associated with symptom change is necessarily the mechanism producing it.

What to keep in mind

Anxiety severity and proposed mediators were assessed using self-report questionnaires; the abstract does not report other study limitations.

Source

Published in Psychother Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.